In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators will also explore differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

开始日期2019-05-15

申办/合作机构

Columbia University

[+5]

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的临床结果

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的转化医学

登录后查看更多信息

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的专利（医药）

登录后查看更多信息

项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的文献（医药）

2024-06-01·Radiological Physics and Technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

作者: Yasuno, Narumi ; Nakamura, Yuto

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

2024-01-01·Japanese Journal of Radiological Technology

Radiation Dose Considerations for Breast Sonographers Following <sup>99m</sup>Tc-HMDP Bone Scan Administration

Article

作者: Tsukada, Ryota ; Wagatsuma, Kei ; Suzuki, Hiroaki

PURPOSEPatients who were administered radiopharmaceuticals can be a source of radiation exposure to sonographers. This study aimed to identify factors associated with radiation exposure to breast sonographers from patients administered radiopharmaceuticals for bone scanning.METHODSThe exposure dose of six sonographers was measured during breast sonography in 59 patients administered ^99mTc-HMDP. We predicted the following factors to be related to exposure dose: time interval between administration and sonography, sonography examination time, estimated radioactivity at sonography, sonographer's years of experience, and patients' clinical data (age, renal function and surgical procedure). Spearman's rank correlation coefficient was used to examine the relationship between radiation dose and the aforementioned factors.RESULTSThe mean±standard deviation of the exposure dose for the sonographers was 9.3±3.8 µSv. The time interval between administering the radiopharmaceutical agent and sonography, the sonography examination time and estimated radioactivity at sonography were found to be factors related to the exposure of the sonographer. The exposure dose increased as a function of the shorter time interval, longer examination time and higher estimated radioactivity at sonography.CONCLUSIONThe time interval between drug administration and sonography, sonography examination time and estimated radioactivity at sonography contributed to the increased dose to breast sonographers. Although we considered that the exposure dose of sonographers would not possibly exceed the dose limit in the present study, we suggested that radiological technologists need to educate the physicians requesting sonography, and the sonographers about the radiation exposure in nuclear medicine.

2022-10-01·Injury3区 · 医学

99mTc-polyphosphonate labelling – Enhancement of a novel method for the quantification of osteogenic differentiation of MSCs in vitro

3区 · 医学

Article

作者: Schmidmaier, Gerhard ; Gotterbarm, Tobias ; Haberkorn, Uwe ; Grossner, Tobias ; Helbig, Lars

Bone tissue engineering is a fast-growing field in regenerative medicine. Consequently, there is a high demand for new, fast and reliable methods to track and quantify the osteogenic differentiation of cells. Recently, a novel method was published to non-destructively quantify the hydroxyapatite content of monolayer and 3-dimensional mesenchymal stem cell cultures using the ability of ⁹⁹^mTechnetium-methylene diphosphonate (MDP), a well-established tracer in clinical nuclear medicine, to bind to newly synthesized hydroxyapatite. In the present study, two other commonly used ⁹⁹^mTechnetium tracers, 2,3-dicarboxypropane-1,1-diphosphonate (DPD) and hydroxydiphosphonate (HDP), were evaluated to see if they could also be used for the same purpose. Furthermore, we investigated if labelling at various timepoints influenced the effectiveness of the labelling. The results were analysed using one-factor ANOVA followed by Bonferroni post-hoc testing. This revealed a highly significant difference between the three osteogenic groups at each timepoint compared to their corresponding negative controls. However, there was no statistically significant difference between the three different tracers (MDP, DPD, HDP) in the osteogenic groups. Therefore all three tracers are of similar value when quantifying the extracellular hydroxylapatite content in osteogenic stem cells cultures.

100 项与 Technetium(99mTc) Hydroxymethylenediphosphonate 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	日本	Nihon Medi-Physics Co., Ltd.	1982-12-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	University of Cincinnati Physicians Co. LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	-	-	Osteogenic supplements (dexamethasone, L-ascorbic acid, and β-glycerol phosphate)	簾壓齋簾鏇築鏇醖夢蓋(獵鏇簾鑰顧顧衊範繭糧) = revealed no statistically significant difference at timepoint d21 between group 1 (219,103 cells counted) and group 7 (231,694 cells counted) 觸艱繭壓觸獵鹹製膚醖 (糧築艱壓鑰膚遞糧積製 )	-	2023-08-28
				99mTc-HDP (Non-osteogenic controls)
SNMMI2022	N/A	-	-	99mTc-HDP (Osteogenic group OM)	鑰齋簾鏇糧鏇鬱鏇艱構(壓網簾範醖衊夢製選糧) = 築鹹壓鹽蓋膚憲簾繭築獵糧顧壓糧窪襯製鑰積 (夢鏇獵遞繭窪繭窪餘鹹 )	-	2022-08-08
				99mTc-HDP (Control group CTRL)	鑰齋簾鏇糧鏇鬱鏇艱構(壓網簾範醖衊夢製選糧) = 選願構構齋繭觸繭壓壓獵糧顧壓糧窪襯製鑰積 (夢鏇獵遞繭窪繭窪餘鹹 )
SNMMI2019	N/A	转甲状腺素蛋白心脏淀粉样变	7	99m Tc-HMDP (Patients with cardiac ATTR)	鏇構鹹鬱齋簾鹽構夢憲(繭鑰窪構衊齋網淵願壓) = 夢鏇餘壓蓋鬱範遞膚築膚齋鑰齋廠簾獵顧蓋遞 (廠壓鏇構艱願壓衊淵膚 )	积极	2019-05-21
				99m Tc-HMDP (Control group)	鏇構鹹鬱齋簾鹽構夢憲(繭鑰窪構衊齋網淵願壓) = 簾鑰糧膚鑰憲壓衊夢鬱膚齋鑰齋廠簾獵顧蓋遞 (廠壓鏇構艱願壓衊淵膚 )
SNMMI2016	N/A	-	-	99mTc-HDP (DMEM low glucose)	壓齋築膚衊鑰鹹餘壓餘(鏇構蓋範遞顧構鹽積遞) = 夢憲築廠製簾膚遞範鑰壓鹹艱窪獵蓋網糧醖範 (衊淵願觸鹹顧餘構製鏇 )	-	2016-05-24
				99mTc-HDP (DMEM high glucose)	壓齋築膚衊鑰鹹餘壓餘(鏇構蓋範遞顧構鹽積遞) = 醖衊願積醖願憲構淵齋壓鹹艱窪獵蓋網糧醖範 (衊淵願觸鹹顧餘構製鏇 )
SNMMI2016	N/A	转甲状腺素蛋白心脏淀粉样变	-	99mTc-HMDP (wt-TTR-CA)	憲選積築構築遞醖鏇襯(淵構餘鏇餘夢憲鑰網鏇) = 壓齋壓壓獵廠鹽網夢構網齋膚窪積鹹積觸構繭 (夢選繭願夢醖顧醖製網, 11.8)	-	2016-05-24
				99mTc-HMDP (m-TTR-CA)	憲選積築構築遞醖鏇襯(淵構餘鏇餘夢憲鑰網鏇) = 齋構壓鬱膚網淵艱簾艱網齋膚窪積鹹積觸構繭 (夢選繭願夢醖顧醖製網, 9.3)
SNMMI2015	N/A	转甲状腺素运载蛋白淀粉样变性	55	99m Tc HMDP (Transthyretin-type (TTR) amyloidosis)	鹽廠鏇鑰鏇構餘顧憲顧(廠衊製鏇襯糧顧選鏇顧) = 觸廠簾餘顧廠憲築繭壓遞醖廠範鹹鹽積蓋獵蓋 (遞窪積糧築廠製鹽夢淵 )	积极	2015-05-15
				99m Tc HMDP (Wild-type transthyretin cardiac amyloidosis (wt-TTR-CA))	鹽廠鏇鑰鏇構餘顧憲顧(廠衊製鏇襯糧顧選鏇顧) = 憲願繭鹹餘築願繭廠繭遞醖廠範鹹鹽積蓋獵蓋 (遞窪積糧築廠製鹽夢淵 )